PPD (Nasdaq: PPDI) will work with a Massachusetts firm to offer more services related to post-drug safety.

, a pharmaceutical and contract research organization working with biotech and life-science companies, struck a co-marketing agreement with .

Financial terms were not disclosed.

The two companies said they would work with each other on a global basis.

“Epidemiology is playing a larger, more important role in understanding and evaluating risks related to drug safety,” said PPD Chief Executive Officer Fred Eshelman. “Our agreement with WHISCON will enhance our ability to help clients identify and manage the benefits and risks of their marketed products.”

PPD employs some 10,500 people worldwide, including 1,000 in the Research Triangle Park area.